HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Rapid clearance of Plasmodium falciparum hyperparasitaemia after oral amodiaquine treatment in patients with uncomplicated malaria.

Abstract
Amodiaquine is one of the possible alternative therapeutic options to treat chloroquine-resistant Plasmodium falciparum infections in Africa. In this study, its efficacy to treat patients with acute uncomplicated falciparum malaria and high parasitaemia (> or =5% of infected erythrocytes in the peripheral blood) was assessed by using the standard protocol developed by the World Health Organization. The mean pre-treatment parasitaemia was 10.8% (range, 5.0-35%). All 32 patients who completed the study (four lost to follow-up) had an adequate clinical and parasitological response on day 14. As compared with the pre-treatment parasitaemia, the mean parasitaemia decreased by 97.8% on day 2 (two patients with negative smears) and 99.97% on day 3 (22 patients with negative smears; the other ten patients had low residual parasitaemia ranging from 24 to 400 asexual parasites/microl). Our results suggest that, in areas of stable transmission in Africa, hyperparasitaemic patients with uncomplicated malaria can be safely treated with oral amodiaquine provided that their clinical and parasitological responses are closely monitored for the first 3 days and controlled on day 7 and 14.
AuthorsMathieu Ndounga, Leonardo K Basco
JournalActa tropica (Acta Trop) Vol. 88 Issue 1 Pg. 27-32 (Sep 2003) ISSN: 0001-706X [Print] Netherlands
PMID12943973 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antimalarials
  • Amodiaquine
Topics
  • Administration, Oral
  • Amodiaquine (administration & dosage, therapeutic use)
  • Animals
  • Antimalarials (administration & dosage, therapeutic use)
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Malaria, Falciparum (drug therapy)
  • Male
  • Parasitemia (drug therapy)
  • Plasmodium falciparum (drug effects)
  • Prospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: